TRAUMEEL® PRODUCT MONOGRAPH12

Traumeel® is a combination of 14 natural ingredients designed to have multiple targets. Latest research including single-molecule transcriptome sequencing demonstrates how a multicomponent, multitarget treatment can potentially promote inflammation resolution and tissue healing.[St Laurent 2017, Jordan 2021] Acceleration of muscle regeneration, via enhancing the expression of pro-myogenic genes and proteins, has also been demonstrated when Traumeel® is used in combination with a calf blood compound.[Langendorf 2019, Belikan 2020] Recent clinical evaluations have supported the potential for Traumeel® to promote inflammation resolution and tissue healing in clinical practice.[Das 2019, Helei 2019]

In a wound-healing model, Traumeel® has been shown to produce biologically significant and consistent changes in hundreds of gene expressions involved in wound healing.[St Laurent 2017] Traumeel s effects on gene expression are consistent with its established effects on inflammation and pain.[St Laurent 2017]

In another model of inflammation, Traumeel® shortened the neutrophil resolution interval by 6 hours.[Jordan 2021] This shortening of the neutrophil resolution interval indicates a reduction in time taken to shift from a proinflammatory response to a proresolution response. Coupled with significantly increased macrophage recruitment,[Jordan 2021] and stimulated synthesis of pro-resolving mediators,[Jordan 2021] evidence for Traumeel s potential to promote inflammation resolution is growing (see Section 4 for more details). All of the formulations of Traumeel® contain 14 components. These are listed in Table 1.

Summary Inflammation is a natural, protective response to acute injury. After the initial inflammatory response (usually within 24 hours), the

inflammatory process should move to inflammation resolution. Current treatment options, while often widely used, find little support when

critically evaluated. Indeed, some are now thought to be detrimental. The cardiovascular and gastrointestinal risks associated with non-steroidal anti-

inflammatory drugs (NSAIDs) restrict their use in a large number of patients. While short-term use of NSAIDs can provide pain relief, their use could impair the

healing process. Corticosteroid injections are commonly used, however, there is very little evidence

that they provide long-term benefit. Traumeel® can provide a different approach to management via the promotion of

inflammation resolution.

OSTEOARTHRITIS

Osteoarthritis (OA), the most common form of joint disease, affects as much as 80% of the general population over the age of 75 years.[Arden 2006] OA of the knee is responsible for 83% of the overall OA-related disability burden.[Vos 2012] The degenerative joint changes that characterize this disorder are radiologically